These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1628965)

  • 1. [Toxic oil syndrome--an example of an exogenously-induced autoimmune disease].
    Bell S; Brand K; Meurer M
    Hautarzt; 1992 Jun; 43(6):339-43. PubMed ID: 1628965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
    Silver RM; Sutherland SE; Carreira P; Heyes MP
    J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Of faddism, toxic oil, and scleroderma.
    Berry CL
    J Pathol; 1993 Aug; 170(4):419-20. PubMed ID: 8410491
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
    Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
    Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The toxic oil syndrome: a perspective on immunotoxicological mechanisms.
    Yoshida SH; German JB; Fletcher MP; Gershwin ME
    Regul Toxicol Pharmacol; 1994 Feb; 19(1):60-79. PubMed ID: 8159816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism.
    del Pozo V; de Andrés B; Gallardo S; Cárdaba B; de Arruda-Chaves E; Cortegano MI; Jurado A; Palomino P; Oliva H; Aguilera B; Posada M; Lahoz C
    Toxicology; 1997 Mar; 118(1):61-70. PubMed ID: 9074654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The toxic oil syndrome: 20 years on.
    Diggle GE
    Int J Clin Pract; 2001; 55(6):371-5. PubMed ID: 11501225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.
    Alonso-Ruiz A; Calabozo M; Perez-Ruiz F; Mancebo L
    Medicine (Baltimore); 1993 Sep; 72(5):285-95. PubMed ID: 8412642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome.
    Carreira PE; Montalvo MG; Kaufman LD; Silver RM; Izquierdo M; Gomez-Reino JJ
    J Rheumatol; 1997 Jan; 24(1):69-72. PubMed ID: 9002013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The toxic oil syndrome (TOS, 1981): from the disease towards a toxicological understanding of its chemical aetiology and mechanism.
    Aldridge WN
    Toxicol Lett; 1992 Dec; 64-65 Spec No():59-70. PubMed ID: 1471212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical-induced autoimmune reactions and Spanish toxic oil syndrome. Focus on hydantoins and related compounds.
    Kammüller ME; Bloksma N; Seinen W
    J Toxicol Clin Toxicol; 1988; 26(3-4):157-74. PubMed ID: 3047417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Bolster MB; Silver RM
    Curr Opin Rheumatol; 1994 Nov; 6(6):642-9. PubMed ID: 7865387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Kaufman LD; Krupp LB
    Curr Opin Rheumatol; 1995 Nov; 7(6):560-7. PubMed ID: 8579979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1993 Nov; 5(6):802-8. PubMed ID: 8117543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
    Maitani T; Saitoh H
    Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
    [No Abstract]   [Full Text] [Related]  

  • 18. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome.
    Bell SA; Hobbs MV; Rubin RL
    J Immunol; 1992 Jun; 148(11):3369-76. PubMed ID: 1588038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Eosinophilia-myalgia: new syndrome].
    Szechiński J; Borysewicz K
    Postepy Hig Med Dosw; 1992; 46(3):319-25. PubMed ID: 1369828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.